Mira Pharmaceuticals announced it has completed the acquisition of subsidiaries associated with SKNY, marking a significant step in broadening its business and research portfolio. The deal, first disclosed earlier this year, is expected to strengthen Mira’s product development capabilities and strategic positioning in emerging therapeutic markets.
The acquisition includes the assumption of certain assets and intellectual property, positioning Mira to integrate SKNY’s expertise in its ongoing pipeline. While financial terms were not disclosed, company representatives emphasized that the transaction creates opportunities for advancing previously underutilized development programs and aligns with Mira’s goal of creating diversified revenue streams.
Mira noted that the closing of the acquisition provides access to additional research platforms, potential new product candidates, and operational synergies, particularly in areas involving cutting-edge therapies and wellness-focused innovations. With the transaction finalized, the company is expected to begin immediate integration efforts, focusing on research coordination and regulatory strategies.
Industry analysts suggest the acquisition demonstrates Mira’s intention to pursue targeted growth through bolt-on transactions rather than large-scale mergers. For SKNY, the move provides continuity for existing programs while leveraging Mira’s resources and expertise to accelerate development. Both companies have indicated their commitment to advancing therapeutic options across multiple healthcare segments.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!